Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds specifically-identified oligosaccharide structure
Patent
1995-06-07
1997-12-30
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds specifically-identified oligosaccharide structure
4241521, 4241721, 5303875, 5303882, 53038825, 5303891, 5303893, 5303913, C07K 1618, A61K 39395
Patent
active
057027048
ABSTRACT:
The circulating advanced glycosylation endproducts Hb-AGE, serum AGE-peptides and urinary AGE-peptides are disclosed as long term markers of diseases and dysfunctions having as a characteristic the presence of a measurable difference in AGE concentration. Diagnostic and therapeutic protocols taking advantage of the characteristics of these AGEs are disclosed. Antibodies which recognize and bind to in vivo-derived advanced glycosylation endproducts are also disclosed. Methods of using these antibodies as well as pharmaceutical compositions are also disclosed, along with numerous diagnostic applications, including methods for the measurement of the presence and amount of advanced glycosylation endproducts in both plants and animals, including humans, as well as in cultivated and systhesized protein material for therapeutic use.
REFERENCES:
patent: 3654090 (1972-04-01), Hermans et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 4016043 (1977-04-01), Schuurs et al.
patent: 4807973 (1989-02-01), Goers et al.
patent: 5223392 (1993-06-01), Cohen
Araki et al. J. Biol. Chem. 267:10211-4 (1992).
Horiuchi, S., et al. J. Biol. Chem. 226 (12):7329-7332 (1991).
Nakayama, H., et al. Biochem. Biophys. Res. Com. 162:740-745 (1989).
Suarez, G., et al. J. Biol. Chem. 264 (7):3674-3679 (1989).
Kennedy et al. Diabetologia 26:93-98. (1984).
Vlassara et al., "Functioin of macrophage receptor for nonenzymatically glycosylated proteins is modulated by insulin levels", Diabetes, 35 Supp. 1, p. 13a (1986).
Vlassara et al., "Accumulation of diabetic rat peripheral nerve myeline by macrophages increases with the prescence of advanced glycosylation endproducts", A. J. Exp. Med 160, pp. 197-207 (1984).
Vlassara et al., "Recognition and uptake of human diabetic peripheral nerve myelin by macrophages", Diabetes, 34 No. 6, pp. 553-557 (1985).
Vlassara et al., "High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senscent macromolecules", Proc. Natl. Acad. Sci. U.S.A., 82, pp. 5588-5592 (Sep. 1985).
Vlassara et al., "Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors", J. Exp. Med. 164, pp. 1301-1309 (1986).
Cerami et al., "Role of nonenzymatic glycosylation in atherogenesis", Journal of Cellular Biochemistry, 30, pp. 111-120 (1986).
Radoff, S. et al., "Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylation end products", Arch. Biochem. Biophys. 263 No. 2, pp. 418-423 (1988).
Yang, Z. et al., "Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins", J. Exp. Med. 174, pp. 515-524 (1991).
Skolnik, E. et al., "Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy", J. Exp. Med., 174, pp. 931-939, 1991.
Makita, Z. et al., "Hemoglobin-age: a circulating marker of advanced glycosylation", Science 258, pp. 651-653, 1992.
Horiuchi, S. et al., "Purification of a receptor for formaldehyde-treated serum albumin from rat liver", J. Biol. Chem., 4, 260, pp. 482-488 (1985).
Takata, K. et al., "Scavenger receptor-mediated recognition of maleylated albumin and its relation to subsequent endocytic degradation", Biochem. Biophys. Acta., 984, pp. 273-280 (1989).
Goldstein, J.L. et al., "Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein , producing massive cholesterol deposition." Proc. Nat'l Acad. U.S.A. 76, pp. 333-337 (1979).
Kirstein, M. et al., "Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging", Proc. Nat'l. Acad. Sci. U.S.A., 87, pp. 9010-9014 (1990).
Fluckiger, R. et al., "Measurement of nonenzymatic protein glycosylation", Methods Enzymol., 106, pp. 77-87 (1984).
Bucala, R. et al., "Characterization of Antisera to the Addition Product Formed by the Nonenzymatic Reaction of 16 3Hydrozyestrone with Albumin", Mol. Immunol., 20, pp. 1289-1292 (1983).
Robard, D. "Statistical Quality Control and Routine Data Processing for Radioimmunoassays and Immunoradiometric Assays", Clin. Chem. 20, pp. 1255-1270 (1974).
McPherson et al., "Role of Fructose in Glycatioinand Cross-Linking of Proteins", Biochemistry, 27, pp. 1901-1907 (1988).
Radoff, S. et al., "Isolation of a Surface Binding Protein Specific for Advanced Glycosylation Endproducts From the Murine Macorphage-Derived Cell Line Raw 264.7", Diabetes, 39, pp. 1510-1518 (1990).
Mitchel, F. et al., "Darstellung Aliphatischer Amadori-Produkte", Chem. Ber., 92, pp.2836-2840 (1959).
Bradford, M., "A Rapid and Sensitive Method for the Quantitation of Mcirogram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Anal. Biochem., 72, pp. 248-252 (1976).
Edward, C. et al., "Modified Assay for Determination of Hydroxyproline in a Tissue Hydrolyzate", Clin. Clim. Acta., 104, pp. 161-167 (1980).
Gaulton et al Ann. Rev. Immunol 4:253-80 1986.
Radoff et al Diabetes 39:1510-1518 1990.
Brownlee et al Annals of Internal Medicine 101:527-537 1984.
Kennedy et al Diabetologia 26:93-98 1984.
Cohen J I Methods 117:121-129 1989.
Makita et al JBL 267(8) 5133-5138 1992.
Cech Emma
Chan Christina Y.
The Rockefeller University
LandOfFree
Antibodies to in vivo advanced glycosylation endproducts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to in vivo advanced glycosylation endproducts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to in vivo advanced glycosylation endproducts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-199985